<DOC>
	<DOCNO>NCT00002582</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen . Combination chemotherapy us different way stop tumor cell divide stop grow die . Combining hormone therapy chemotherapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness tamoxifen without chemotherapy and/or ovarian ablation treat woman stage I , stage II , stage IIIA breast cancer .</brief_summary>
	<brief_title>Tamoxifen , Ovarian Ablation , and/or Chemotherapy Treating Women With Stage I , Stage II , Stage IIIA Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Estimate overall relapse-free survival woman early-stage breast cancer receive adjuvant tamoxifen without adjuvant chemotherapy and/or ovarian suppression . OUTLINE : This randomize , multicenter study . Patients stratify participate institution choice randomization option . Postmenopausal woman randomize first second group . Randomization pre- perimenopausal woman base clinician 's judgement appropriate adjuvant therapy ( chemotherapy and/or ovarian suppression ) . Patients may randomize follow : among four group ; chemotherapy alone ( first versus second group ) ; ovarian suppression alone ( first versus third group ) ; ovarian suppression nonrandomized assignment chemotherapy ( second versus forth group ) ; chemotherapy nonrandomized assignment ovarian suppression ( second versus fourth group ) . - First group : Patients receive tamoxifen mouth every day 5 year . - Second group : Patients receive tamoxifen plus cyclophosphamide , methotrexate , fluorouracil ( CMF ) doxorubicin/cyclophosphamide ( AC ) . CMF give every month 6 course ; AC give every 3 week 4 course . - Third group : Patients receive tamoxifen plus ovarian suppression oophorectomy , radiation castration , leuprolide goserelin . - Fourth group : Patients receive tamoxifen plus ovarian suppression plus chemotherapy CMF AC . Patients follow overall relapse-free survival . PROJECTED ACCRUAL : Approximately 6,000 woman ( 4,000 premenopausal , 2,000 postmenopausal ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive carcinoma breast adjuvant systemic therapy appropriate Stage I , II , IIIA Pathologically positive negative node Any size primary tumor No edema , peau d'orange , infiltration skin , direct extension chest wall Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Pre , peri , postmenopausal Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior malignancy except : Basal cell carcinoma Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : Not specify Other : No prior systemic treatment breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>